LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Mike Lobinsky, Pierre Schwich Now at EOS imaging
Company News

Mike Lobinsky, Pierre Schwich Now at EOS imaging

August 17, 2017 2 min read Premium comments

Advertisement

Mike Lobinsky, Pierre Schwich Now at EOS imaging
(L to R): Mike Lobinsky and Pierre Schwich / Courtesy of EOS imaging and Lesechos.fr
Secondary

Mike Lobinsky and Pierre Schwich have come on board at Paris, France-based EOS imaging, with Lobinsky taking on the position of President, North America and Schwich assuming the position of chief financial officer (CFO).

The company wrote in its July 18, 2017 news release, “Lobinsky has formerly served as U.S. Vice President, Sales and Implementation – Robotics at Smith & Nephew, which he joined through their 2016 acquisition of Blue Belt Technologies, a global leader in surgical robotics. At Blue Belt, he served as Vice President, Sales, leading all sales related activities for the company’s Navio surgical system, which provides robotics-assistance in knee replacement surgery. From 2006 to 2013, Lobinsky served in roles of increasing responsibly at BioMedix Vascular Solution, most recently as Vice President, Sales and Marketing.”

“Pierre Schwich brings over 20 years of experience in Financial Management at high growth, public and private companies in the healthcare and technology sectors. Before joining EOS imaging, he was CFO of Pharnext, where he successfully led the company’s initial public offering. He was previously Financial and Legal Director of Oceasoft, a company specialized in connected sensors, and CFO of Cellectis where he contributed to a private placement with U.S. investors. Pierre was also Deputy CEO, in charge of finances, of Genesys Conferencing, a public company listed in Paris and on the NASDAQ, with a strong activity in the U.S.”

Pierre Schwich told OTW, “I am very excited to join EOS imaging at a stage when the company has already proven its uniqueness in imaging solutions for musculoskeletal pathologies through its technology platform. The company, listed on Euronext since 2012, also benefits from a highly professional governance with appropriate quality and compliance rules.”

“Over the coming weeks, I will complete my full understanding of the development, manufacturing and selling processes to further secure them and contribute to their improvement. I will also be focused on investor relations in order to increase our awareness within the financial community and gain interest from European and American investors. I am convinced of the exceptional potential of EOS imaging, and my role beyond the first six months will be to ensure the company has the financial organization and means to support its fast development.”

Mike Lobinsky commented to OTW, “I have always been impressed with the EOS technology and what the company has accomplished. It’s an exciting time to come on board. We are experiencing rapid growth in North America as EOS is the standard of care for hospitals that prioritize safe imaging and patient-specific treatments. To ensure that we have the staff to address the needs of our current and future customers, one of my main focuses will be to grow our North American applications, service, and sales teams. This will help us continue to deliver the high level of service our customers are used to receiving as well as drive the adoption of our advanced orthopedic solutions for the spine, hip, and knee.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy